A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children

Trial Profile

A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT Used In The Treatment Of Upper Limb Spasticity In Children

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms PUL
  • Sponsors Ipsen
  • Most Recent Events

    • 28 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2018.
    • 15 Sep 2016 Results of a pooled analysis from 8-trials will be presented at the annual meeting of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM), as reported by Ipsen Biopharmaceuticals media release.
    • 26 Feb 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top